Titre
All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS).
Type
recension de livre
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Roelens, M.
Auteure/Auteur
Bertisch, B.
Auteure/Auteur
Moradpour, D.
Auteure/Auteur
Cerny, A.
Auteure/Auteur
Semmo, N.
Auteure/Auteur
Schmid, P.
Auteure/Auteur
Müllhaupt, B.
Auteure/Auteur
Clerc, O.
Auteure/Auteur
Semela, D.
Auteure/Auteur
Junker, C.
Auteure/Auteur
Negro, F.
Auteure/Auteur
Keiser, O.
Auteure/Auteur
Contributrices/contributeurs
Negro, F.
Kaiser, L.
Heim, M.
Hirsch, H.
Semmo, N.
Suter, F.
Moradpour, D.
Aubert, V.
Siegrist, H.
Cerny, A.
Martinetti-Lucchini, G.
Clerc, O.
Semela, D.
Schmid, P.
Dollenmaier, G.
Müllhaupt, B.
Probst-Müller, E.
Benkert, P.
Fabbro, T.
Rutquist, M.
Sluka, C.
Groupes de travail
Swiss Hepatitis C Cohort Study
Liens vers les personnes
Liens vers les unités
ISSN
2328-8957
Statut éditorial
Publié
Date de publication
2020-08
Volume
7
Numéro
8
Première page
ofaa308
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
With direct-acting antiviral agents (DAAs), mortality rates and causes of death among persons with hepatitis C virus (HCV) infection may change over time. However, the emergence of such trends may be delayed by the slow progression of chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited.
We evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office death registry.
We included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for liver-related mortality than those never treated or treated unsuccessfully.
Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.
We evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal Statistical Office death registry.
We included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for liver-related mortality than those never treated or treated unsuccessfully.
Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued monitoring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.
PID Serval
serval:BIB_BFF9FB92C478
PMID
Open Access
Oui
Date de création
2020-09-09T09:46:10.957Z
Date de création dans IRIS
2025-05-21T01:58:22Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32855989_BIB_BFF9FB92C478.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by-nc-nd/4.0
Taille
308.78 KB
Format
Adobe PDF
PID Serval
serval:BIB_BFF9FB92C478.P001
URN
urn:nbn:ch:serval-BIB_BFF9FB92C4780
Somme de contrôle
(MD5):9c8d4760154b39c75058187e6033f897